Nearly 90 percent of patients with an aggressive subtype of non-Hodgkin lymphoma had their cancer go into remission in a small phase 2 clinical trial testing a treatment aimed at making chemotherapy more effective, according to Weill Cornell...
Read more
Dear Members of the Englander Institute, As we begin the last month of the year I’d like to thank all of you for your hard work, productivity, and dedication to our mission. It’s a great pleasure to work along side you, and I can...
Read more
Dear Members of the Englander Institute, I’m really happy to share this month’s EIPM Director’s Memo with you because there are so many great new initiatives, partnerships, news coverage, events, and publications to celebrate!...
Read more
August 2022 EIPM Director’s Memo Dear Members of the Englander Institute,Congratulations to Dr. Jedd Wolchok, a highly esteemed physician-scientist who pioneered immunotherapy for the treatment of melanoma, on becoming the new Director of...
Read more
Fall 2021 Englander Institute Newsletter October 2021 Dear Friend of the Englander Institute for Precision Medicine, Welcome to our third quarterly newsletter of 2021, we hope you enjoy learning more about the important progress...
Read more
August 2021 EIPM Director’s Memo Dear Members of the Englander Institute, I hope you’re enjoying the summer and continuing to stay healthy. We are closely monitoring the rise of the Delta variant, and encourage everyone to get...
Read more
Summer 2021 EIPM External Newsletter July 2021 Dear Friend of the Englander Institute for Precision Medicine, Welcome to our second quarterly newsletter of 2021! Thank you for signing-up on our website to receive this newsletter, we hope you...
Read more
Dr. John Leonard Named Inaugural Senior Associate Dean for Innovation and Initiatives Dr. John Leonard, an esteemed physician-scientist who specializes in lymphoma research and treatment, has been named senior associate dean for innovation and...
Read more
Rituximab Plus Lenalidomide More Effective Against Indolent Lymphoma Than Rituximab Alone The addition of an oral immunomodulatory drug to a commonly employed antibody therapy is more effective against chronic, indolent lymphoma than the antibody ...
Read more